Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis part II

Digestive Diseases and Sciences

Volumn 27, Issue 9, 1982, Pages 833-856

  Bachrach, William H ^a,b   Hofmann, Alan F ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ZAMBON;

ACUTE PANCREATITIS; ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCIFICATION; CHOLELITHIASIS; CHOLESTEROL STONE; DIARRHEA; DIGESTIVE SYSTEM; GALLBLADDER; GALLSTONE; GALLSTONE DISSOLUTION; GASTROINTESTINAL SYMPTOM; LIPID BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PANCREAS; PRURITUS; RADIOLUCENCY; REVIEW; THERAPY;

ANIMAL; CHENODEOXYCHOLIC ACID; CHOLELITHIASIS; CHOLESTEROL; CLINICAL TRIALS; COMMON BILE DUCT CALCULI; COMPARATIVE STUDY; DEOXYCHOLIC ACID; HUMAN; INTESTINES; LIVER; RECURRENCE; SUPPORT, U.S. GOV'T, P.H.S.; URSODEOXYCHOLIC ACID;

EID: 0019976525     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/BF01391378     Document Type: Review

References (323)

1. Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism
2. A multicentre clinical trial on ursodeoxycholic acid: effect of different dosages upon cholesterol gallstone dissolution
3. Lithocholate metabolism during chenotherapy for gallstone dissolution. 2. Absorption and sulfation
4. Lithocholate metabolism during chenotherapy for gallstone dissolution. 1. Serum levels of sulphated and unsulphated lithocholates
5. Serum levels of individual bile acids in portal venous and systemic circulation during treatment with chenodeoxycholic acid and cholic acid
6. Degradation of steroids by intestinal bacteria. II. Enzymes catalysing the oxidoreduction of the 3α, 7α-, and 12α-hydroxyl groups in cholic acid, and the dehydroxylation of the 7-hydroxyl group
7. Effect of low doses of ursodeoxycholic acid on biliary lipid composition in nonobese gallstone patients
8. Effect of ursodeoxycholic acid on biliary lipid composition. A double blind study
9. Studies on ursodeoxycholic acid tolerance test in hepatobiliary diseases with special reference to dynamic changes of individual serum bile acids
10. Diminished enzymatic bile salt sulfation in rhesus monkeys
11. Analysis of response to ursodeoxycholic acid for gallstone dissolution
12. Effect of gallstone dissolution therapy on human liver structure
13. Gallstone Calcification caused by ursodeoxycholic acid
14. Effect of prolonged chenodeoxycholic acid feeding on bile in patients with and without gallstones
15. Effect of prolonged feeding with chenodeoxycholic acid on bile in patients with and without gallstones
16. Ursodeoxycholic acid therapy and biliary lipids—a dose-response study
17. Can a six-month cholecystogram predict eventual response to gallstone dissolution therapy?
18. The effect of feeding tauroursodeoxycholic acid on biliary bile acid composition
19. Ursodeoxycholic acid in the dissolution of cholesterol gallstones: a blind-controlled trial
20. Lithocholic acid (LC) is formed from chenodeoxycholic (CDC) and ursodeoxycholic (UDC) acids at a similar rate
21. The value of radiology in predicting gallstone type when selecting patients for medical treatment
22. Gallstone dissolution in man using chenodeoxycholic acid
23. Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis
24. Pharmacology of chenodeoxycholic acid. II. Absorption and metabolism
25. Effects of ursodeoxycholic acid on biliary lipid secretion in patients with radiolucent gallstones
26. Decreased cholesterol absorption during ursodeoxycholic acid administration
27. Bile acids and steroids. 82: On the mechanism of deoxycholic acid formation in the rabbit
28. The site of absorption of conjugated bile salts in man
29. Liver ultrastructure in gallstone patients before and after chenotherapy
30. Dose-related effects of chenodeoxycholic acid in the rabbit colon
31. Inhibition of chenodeoxycholic acid induced secretion in the rabbit colon
32. Chenodeoxycholic acid vs ursodeoxycholic acid in biliary tract dynamics in cholecystectomized patients
33. Clinical experiences concerning gallstones dissolution with ursodeoxycholic acid
34. Metabolism of bile acids with special reference to liver injury
35. Physical-chemical basis for dissimilar intraluminal solubilities and intestinal absorption efficiencies of chenodeoxycholic acid and ursodeoxycholic acid
36. The importance of total lipid concentration in determining cholesterol solubility in bile and the development of critical tables for calculating “percent cholesterol saturation” with a correction factor for ursodeoxycholate-ric bile
37. Thermodynamic and molecular basis for dissimilar cholesterol solubilizing capacities by micellar solutions of bile salts; cases of sodium chenodeoxycholate and sodium ursodeoxycholate and their glycine and taurine conjugates
38. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man
39. Solution properties of sulfated monohydroxy bile salts. Relative insolubility of the disodium salt of glycolithocholate sulfate
40. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: Comparative effects of short-term feeding of chenodeoxycholic and ursodeoxycholic acid
41. Comparative effects of urso- and chenodeoxycholic acid on colonic and small intestinal function in rats
42. Chenodeoxycholic acid (CDCA) versus ursodeoxycholic acid (UDCA): a comparison of their effects in pregnant rats
43. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon
44. Functional and ultrastructural changes in the liver during CDCA treatment
45. Cholesterol balance and fecal neutral steroid and bile acid excretion in normal men fed dietary fats of different fatty acid composition
46. Mesophase formation during cholesterol dissolution in ursodeoxycholate-lecithin solutions: new mechanism for gallstone dissolution in humans
47. Comparison of antacids on the binding of bile salts
48. Metabolism of lithocholate in healthy man. I. Biotransformations and biliary excretion of intravenously administered lithocholate, lithocholyglycine, and their sulfates
49. Metabolism of lithocholate in healthy man. II. Enterohepatic circulation
50. Metabolism of lithocholate in healthy man. III. Plasma disappearance of radioactivity after intravenous injection of labeled lithocholate and its derivatives
51. Untersuchungen zur kokarzinogenen Wirkung von Ursodeoxycholsäure and Chenodeoxycholsäure beim Dimethylhydrazine-induzierten Kolonkarzinom der Ratte
52. DNA synthesis in the rat colon: Influence of chenodeoxycholic acid and ursodeoxycholic acid
53. Effect of chenodeoxycholic acid and ursodeoxycholic acid on liver cell proliferation in the rat—a morphometric and histoautoradiographic study
54. Dissolution of cholesterol gallstones by chenodeoxycholic acid
55. Capacity of the human colon to absorb fluid
56. Traitement de la lithiase biliaire par l'acide ursodéoxycholique
57. Human intestinal sulfation of lithocholate: a new site for bile acid metabolism
58. Bile acid metabolism. I. Studies on the mechanisms of intestinal transport
59. Identification of patients with cholesterol or pigment gallstones by discriminant analysis of radiographic features
60. Medical treatment of gallstones with CDCA and UDCA
61. Effects of controlled interruption of the enterohepatic circulation of bile salts by biliary diversion and by ileal resection on bile salt secretion, synthesis, and pool size in the rhesus monkey
62. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport
63. Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by human intestinal lecithinase-lipase-negative Clostridia
64. Metabolism of taurolithocholic acid in the hamster
65. Metabolism of ursodeoxycholic acid in man
66. Transformation of chenodeoxycholic and ursodeoxycholic acid by human intestinal bacteria
67. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid in the rhesus monkey. Biochemical and ultrastructural studies
68. A prospective morphologic evaluatin of hepatic toxicity of chenodeoxycholic acid (CDCA) in patients with cholelithiasis
69. Mechanisms of hepatic bile formation
70. Ursodeoxycholic acid (UDCA) in the treatment of dyspepsia: report of a multicenter controlled trial
71. Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids
72. Veränderungen des Gallensäurenstoffwechsels unter der Behandlung mit Chenodesoxycholsäure. Untersuchungen zur Bedeutung des Auftretens von Ursodesoxycholsäure fur die Gallensteinauflösung
73. Impaired lithocholate sulfation in the rhesus monkey: a possible mechanism for chenodeoxycholate toxicity
74. Laboratory and clinical investigations after ursodeoxycholic acid treatment. Preliminary observations on uric acid excretion in bile
75. Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease
76. Structure of bile acids associated with secretion in the rat cecum
77. Mechanism of cholestasis. 6. Bile acids in human livers with or without biliary obstruction
78. Mechanism of cholestasis. 5. Bile acids in normal rat livers and in those after bile duct ligation
79. A physiologic method for estimation of hepatic secretion of biliary lipids in man
80. Acute effects of individual bile acids given enterally on biliary lipid secretion in the hamster
81. Biliary lipid secretion in the hamster: Greater cholesterol secretion induced by unconjugated bile acids
82. Isolated fecal microorganisms capable of 7α-dehydroxylating bile acids
83. Untersuchungen über die Gallen einiger Polarthiere. I. Ueber die Galle des Eisbären. I Abschnitt
84. Enrichment of bile with taurine-conjugated ursodeoxycholic acid in hamsters
85. Studies on calcified structure in human cholesterol gallstone
86. Determinants of bile acid Tm in the rat
87. Individual differences in cancer susceptibility
88. Light and electron microscopy of human liver before and during chenodeoxycholic acid therapy
89. Structural specificity of bile acid for inhibition of sterol synthesis in cell-free extracts of yeast
90. Induced synthesis of alkaline phosphatase by bile acids in rat liver cell culture
91. Bile acids modify alkaline phosphatase induction and bile secretion pressure after bile duct obstruction in the rat
92. Getting rid of gallstones without surgery
93. Microbiological transformation of bile acids
94. The solubility of cholesterol in aqueous solutions of bile salts and lecithin
95. On the origin of lithocholic and ursodeoxycholic acids in man. Bile acids and steroids 106
96. Interconversion between chenodeoxycholic and ursodeoxycholic in anaerobic cultures of intestinal bacteria and reduction of 7-ketolithocholic acid to both bile acids
97. Epidemiology and etiology of gallstones
98. Epimerization of the 7-hydroxy group of bile acids by the combination of two kinds of microorganisms with 7α- and 7β-hydroxysteroid dehydrogenase activity, respectively
99. In vitro transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal flora, with particular reference to the mutual conversion between the two bile acids
100. Physical-chemical properties of chenodeoxycholic acid and ursodeoxycholic acid
101. Measurement of bile acid kinetics by isotope dilution in man
102. Characterization of bile acid metabolism in man using bile acids labelled with stable isotopes
103. Chenotherapy for gallstone dissolution. II. Induced changes in bile composition and gallstone response
104. Metabolism of bile acids. I. Absorption, distribution, excretion and metabolism of ursodeoxycholic acid
105. Acute toxicity and hemolysis studies of ursodeoxycholic acid in rats and mice
106. Ursodeoxycholate—a common bile acid in gall bladder bile of Japanese subjects
107. Cholesterol monohydrate (ChM) gallstones dissolved faster in chenodeoxycholate (CDC)-rich bile than in ursodeoxycholate (UDC)-rich bile
108. pH-solubility relations of chenodeoxycholic and ursodeoxycholic acids: Physical-chemical basis for dissimilar solution and membrane phenomena
109. Cholesterol gallstone dissolution in bile: Dissolution kinetics of crystalline (anhydrate and monohydrate) cholesterol with chenodeoxycholate, ursodeoxycholate, and their glycine and taurine conjugates
110. Ursodeoxycholate—in vitro cholesterol solubility and changes of composition of human gallbladder-bile after oral treatment
111. A medical treatment for gallstones?
112. Chenodiol for gallstones: Dissolution or disillusion?
113. Clinical studies on cheno- and ursodeoxycholic acid treatment for gallstone dissolution
114. Über die Konstitution der Urso-desoxycholsäure
115. Solubility of cholesterol and gallstones in metabolic material
116. Ultrastrukturelle Untersuchungen der Leber bei Patienten mit Cholesteringallensteinen unter Chenodesoxycholsäure-therapie
117. Treatment of gallstones with chenodeoxy- and ursodeoxycholic acid; the influence of presence or absence of hyperlipidemia on gallstone dissolution
118. Efficacy and indications of ursodeoxycholic acid treatment for dissolving gallstones. A multi-center doubleblind trial
119. Studies on the synthesis of ursodeoxycholic acid
120. Abnormality of oral ursodeoxycholic acid tolerance test in the Dubin-Johnson syndrome
121. Effects of diet on the fecal excretion and bacterial modification of acidic and neutral steroids, and implications for colon carcinogenesis
122. Transformation of hamster embryo cells by cholesterol-α-epoxide and lithocholic acid
123. Cytotoxicity of bile acids on cultured cells
124. Solubilization of cultured cell membrane by bile acids
125. Tauroursodeoxycholate prevents taurocholate induced cholestasis
126. Biliary transport maximum of tauroursodeoxycholate is twice as high as that of taurocholate in the rat
127. Effect of chenodeoxycholic acid on liver structure and function in man: A stereological and biochemical study
128. Effect of ursodeoxycholic acid on liver structure in man: Quantitative data
129. Production by lithocholic acid of DNA strand breaks in L1210 cells
130. Der Einfluss oraler Cholelitholytika auf die Resorption von Digitoxin
131. Bile acids in tumor tissue, intestinal mucosa, serum, and feces of patients with colorectal carcinoma
132. Differences in chenodeoxycholic acid and ursodeoxycholic acid influence on rat small intestinal wall bile acids
133. Unterschiedlicher Einfluss von Chenodeoxycholsäure (CDC) and Ursodeoxycholsäure (UDC) auf die Gallensäuren in Kolonwand und Koloninhalt der Ratte
134. Effectiveness of ursodeoxycholic acid in gallstone therapy
135. Effect of ursodeoxycholic acid on bile supersaturated with cholesterol in patients pretreated with clofibrate
136. Étude histologique et histoenzymologique du foie. II. Dans la lithiase vésiculaire traitée par l'acide chénodésoxycholique
137. Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients
138. Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption
139. Effect of ursodeoxycholic acid and chenodeoxycholic acid absorption in patients with cholelithiasis
140. Ursodeoxycholic acid ingestion after ileal resection: effect on biliary bile acid and lipid composition
141. Dissolving hopes for gallstone dissolution?
142. Effect of ursodeoxycholic acid on bile acid kinetics and hepatic lipid secretion
143. Effects of bile acid feeding on lipoprotein concentration, change in cholesterol synthesis and biliary lipid secretion in patients with radiolucent gallstones
144. Bilanz der medikamentösen Gallenstein Auflösung
145. Morphologische Untersuchungen zur Toxizität sulfatierter und nichtsulfatierter Lithocholsäure an der perfundierten Rattenleber
146. Gallstone dissolution in patients with chronic active hepatitis
147. Untersuchungen zur Wirksamkeit von Ursodeoxycholsäure und Chenodeoxycholsäure bei vergleichbaren Kollectiven von Gallensteinpatienten
148. Der Einfluss von Chenodesoxycholsäure und Ursodesoxycholsäure auf die Leberstruktur der Ratte
149. Prediction of gallstone type by bile acid analysis of human gallbladder bile
150. Effects of taurochenodeoxycholic and tauroursodeoxycholic acids on gastric mucosa
151. Cholecystectomy and carcinoma of the colon
152. Risk factors and preventive measures in the control of cancer of the large intestine
153. Formation of urso- and ursodeoxycholic acids from primary bile acids by Clostridium absonum
154. Bile acids. VIII. Metabolism of 7-ketolithocholic acid-24-C14 in the rat
155. Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid
156. Dissolution of cholesterol gallstones by ursodeoxycholic acid
157. L'état de la circulation enterohepatique influence-t'il l'action immediate de differents sels biliares sur la saturation de la bile en cholesterol
158. Bioverfügbarkeit von Ursodeoxycholsäure bei der Gallensteinauflösung des Menschen: Massenspektrometrische Studien mit13C-markierter Ursodeoxycholsäure
159. Bioavailability of ursodeoxycholic acid in man: Studies with a radioimmunoassay for ursodeoxycholic acid
160. Hepatic cholesterol synthesis in cholelithiasis: role of HMGCoA reductase in response to and resistance to medical therapy
161. Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids
162. Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action
163. Bile acids I. Two new acids from rat bile
164. Quasielastic light scattering studies of aqueous biliary lipid systems. Size, shape and thermodynamics of bile salt micelles
165. Best buy bile acid treatment for gallstones
166. The National Cooperative Gallstone Study Report: A surgeon's perspective
167. An explanation for bile acid mediated gastritis and the relief of dyspepsia with chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) therapy
168. Erfahrungen mit der Medikamentösen Gallensteinauflösung
169. Biliary lipid metabolism in obesity. Effects of bile acid feeding before and during weight reduction
170. Cholesterol and bile acid absorption during bile acid therapy in obese subjects undergoing weight reduction
171. Comparaison des propriétés micellaires et tensioactives des acides chénodésoxycholique (CDC) et ursodésoxycholique (UDC) et de leurs tauro (T-) et glyco (G-) conjugués en solution diluée
172. Diet, fecal bile acids, and neutral sterols in carcinoma of the colon
173. Dissolution of cholesterol gallstones by ursodeoxycholic acid
174. Studies on the mechanism of the serum cholesterol lowering effect of ursodeoxycholic acid. Hepatic cholesterol biosynthesis and fecal excretion of end products of cholesterol metabolism
175. Effects of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) to glucose transport in hamster small intestine, in vitro. A study on the mechanism of diarrhea due to CDCA therapy
176. Some cases of gallstones dissolved by bile acid preparations
177. Effect of chenodeoxycholic and ursodeoxycholic acids on isolated human hepatocytes
178. Effect of bile acids and dietary fat on large bowel carcinogenesis in animal models
179. Tissue distribution of cholylglycine-1-14C in rats and hamsters with a bile fistula or bile duct ligation
180. Bile acids and intestinal cancer
181. Biliary lipid secretion in gallstone patients
182. Biliary lipid output during three meals and an overnight fast. I. Relationship to bile acid pool size and cholesterol saturation of bile in gallstone and control subjects
183. Biliary lipid output during three meals and an overnight fast. II. Effect of chenodeoxycholic acid treatment in gallstone subjects
184. Ursodeoxycholic acid tolerance test in patients with constitutional hyperbilirubinemias and effect of phenobarbital
185. Clinical studies on dissolution of gallstones using ursodeoxycholic acid
186. Metabolism of bile acids IV. Absorption, distribution, excretion and metabolism of orally administered ursodeoxycholic acid in rats
187. Metabolism of bile acids V. Metabolism of ursodeoxycholic acid in rhesus monkey
188. Metabolism of bile acids VII. Metabolism of ursodeoxycholic acid in female rats
189. Bile acids, liver injury, and liver disease
190. Lithocholate metabolism in baboons ingesting chenodeoxycholic acid
191. Human cholesterol (ChM) gallstones dissolve as fast in simulated ‘urso’-rich bile as in ‘cheno’-rich bile
192. Pharmacokinetics and metabolism of [14C]-ursodeoxycholic acid in the rat
193. Cholesterol gallstone formation and prevention by chenodeoxycholic and ursodeoxycholic acids. A new hamster model
194. Die Cholezystektomie als prädisponierender Faktor in der Genese des kolorektalen Karzinoms?
195. A hamster embryo cell model system for identifying carcinogens
196. Morphological transformation of early passage golden Syrian hamster embryo cells derived from cryopreserved primary cultures as a reliable in vitro bioassay for identifying diverse carcinogens
197. A combination of cheno- and ursodeoxycholic acid is more effective than either alone in reducing bile cholesterol saturation
198. Comparison of effects of cheno-, urso-deoxycholic acid and their combination on biliary lipids in obese patients with gallstones
199. Fecal bile acid excretion in diarrhea: Effect of sulfated and non-sulfated bile acids on colonic structure and function
200. The effect of ursodeoxycholic acid (UDCA) on “dyspepsia” in patients with gallstones or other biliary tract anomalies
201. Treatment of radiolucent gallstones with CDCA or UDCA. A multicenter trial
202. The influence of bile acid pool composition on the regulation of cholesterol absorption
203. Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration
204. Effect of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) on cholesterol absorption in man
205. Clinical pharmacology of oral chenodeoxycholic acid
206. Hepatic extraction of bile salts in conscious dog
207. Increased glycine conjugation of biliary bile acids during treatment of gallstone patients with chenodeoxycholic acid or ursodeoxcholic acid: Effects on biliary cholesterol saturation
208. Kinetics of cholesterol gallstone dissolution by glycocheno-, glyco-urso-deoxycholic acid, and mixtures of both in vitro
209. The effect of hydroxy bile acids on intestinal secretion, cyclic nucleotides, and Na+−K+-ATPase
210. Ursodeoxycholic acid. Effects on sterol metabolism in rats
211. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps
212. The disappearance of gallstone shadows following the prolonged administration of bile salts
213. Comparative effects of cholic, chenodeoxycholic and ursodeoxycholic acids on micellar solubilization and intestinal absorption of cholesterol
214. Effect of chenodeoxycholic acid and ursodeoxycholic acid administration on biliary lipid secretion in normal weight and obese gallstone patients
215. Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients
216. Gas-liquid chromatic assay of serum bile acids
217. Is recurrence inevitable on withdrawing treatment after complete dissolution with chenodeoxycholic (CDC) and ursodeoxycholic (UDC) acids?
218. The effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans
219. The metabolism of ursodeoxycholic acid in man
220. Increased formation of ursodeoxycholic acid in patients treated with chenodeoxycholic acid
221. The metabolism of 7-ketolithocholic acid in man
222. Crystalline cholesterol monohydrate (ChM) dissolves in ‘urso’-rich bile by both liquid crystalline and micellar mechanisms: A phase equilibria explanation and possible clinical relevance
223. Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones
224. Ursodeoxycholic acid therapy for radiolucent gallstone dissolution
225. Intracolonic conversion in man of chenodeoxycholic acid (CDC) to ursodeoxycholic acid (UDC) with and without formation of 7-ketolithocholic acid (KLC) as an intermediate
226. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and on bile acid composition in the rhesus monkey
227. Biliary cholesterol output during ursodeoxycholic acid secretion in man
228. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. A controlled trial of efficacy and safety
229. Bile acid conjugation in the chimpanzee: Effective sulfation of lithocholic acid
230. A problem in the evaluation of gallstone dissolution
231. Deconjugation of bile acids by intestinal bacteria. Review of literature and additional studies
232. Pharmacokinetic study of oral ursodeoxycholic acid tolerance test
233. Über die Ursodesoxycholsäure aus Bärengallen und ihre physiologische Wirkung
234. Bile acids: Co-mutagenic activity in the Salmonella-mammalian-microsome mutagenicity test: Brief communication
235. The occurrence of 7β-hydroxylated bile acids in human bile. Bile acids and steroids 76
236. Effects of chenodeoxycholic acid and ursodeoxycholic acid on bile acid and biliary lipid metabolism in patients with radiolucent gallstones. Correlation with efficacy and toxicity
237. Zur Ursache erhöhter Serumtransaminasen nach Behandlung von Patienten mit Cholesteringallensteinen mit Chenodeoxycholsäure
238. Urosodeoxycholic acid versus chenodeoxycholic acid. Comparison of their effects on bile acid and bile lipid composition in patients with cholesterol gallstones
239. Sulphation lithocholate in patients during chenodeoxycholate treatment. A protective mechanism
240. Increasing sulfation of lithocholate in patients during chenodeoxycholate therapy
241. Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid
242. Lithocholate sulfation: A determinant of hypertransaminesia in chenodeoxycholate-treated gallstone patients
243. Retrospective studies on gallstone disappearance
244. Toxicity studies of ursodeoxycholic acid orally administered for three months in Wistar male rat
245. Chronic toxicity studies of ursodeoxycholic acid orally administered for six months in Wistar male rat
246. Subacute toxicity studies of orally administered ursodeoxycholic acid in Wistar rat
247. Subacute toxicity studies of intraperitoneally administered ursodeoxycholic acid in Wistar rat
248. Influence of ursodeoxycholic acid administered during pregnancy on the development of foetus and postnatal growth in rats and mice
249. Effect of β-sitosterol alone or in combination with chenic acid on cholesterol saturation of bile and cholesterol absorption in gallstone patients
250. Oral ursodeoxycholic acid tolerance test for patients with hepatobiliary disease
251. Bile acid composition affecting cholesterol dissolution rate: A use of multiple regression analysis
252. Treatment of bile duct stones
253. Chenotherapy for gallstone dissolution. I. Efficacy and safety
254. Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man: A dose-response study
255. Serum lipoprotein cholesterol changes during bile acid ingestion for gallstone dissolution
256. XIX. Metabolism of lithocholic acid-24-14C in the rat
257. Ursodeoxycholic acid: a clinical trial of a safe and effective agent for dissolving cholesterol gallstones
258. Serum bile acids after test meals and oral load of chenodeoxycholic acid
259. Die Behandlung eines Syndroms von dyspeptischen Beschwerden mit Ursodeoxycholsäure
260. Reproduction studies of ursodeoxycholic acid in rats. (II) Teratogenicity study
261. Reproduction studies of ursodeoxycholic acid in rats. (4) Perinatal and postnatal study
262. Reproduction studies of ursodeoxycholic acid in rats. (1) Fertility study
263. Teratogenicity study of ursodeoxycholic acid in rabbits
264. Evaluation of radiographic lucency or opaqueness of gallstones as a means of identifying cholesterol or pigment stones; correlation of radioopaqueness with mineral content
265. Cholecystectomy and right-sided colon cancer: An epidemiological study
266. A cross-over double-blind trial comparing the effects of ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) on bowel habit in man
267. Indication a la dissolution médicale de la lithiase biliaire et valeur de la détermination de l'index lithogene
268. Ultrastructural studies on the preventive effect of ursodeoxycholic acid in possible alloxan-induced pancreatic injury
269. Bile salt absorption; enterohepatic circulation
270. Clinical experience in bile composition in patients taking ursodeoxycholic acid for gallstone dissolution
271. Biliary excretion of lecithin and cholesterol in the dog
272. Prediction of the bile acid composition of bile from serum bile acid analysis during gallstone dissolution therapy
273. Effect of ursodeoxycholic acid (UDCA) on primary bile acid kinetics in gallstone patients
274. Effect of ursodeoxycholic acid (UDCA) on serum total and VLDL triglycerides in gallstone patients
275. Ursodeoxycholic acid toxicity in rabbits
276. Effects of some bile acids on hepatic blood flow in dogs-with reference to biliary excretion
277. Choleretic properties of ursode-oxycholic acid and chenodeoxycholic acid in dogs
278. Lithocholate cholestasis—sulfated glycolithocholate-induced intrahepatic cholestasis in rats
279. Is the saturation index predictive for gallstone dissolution during treatment with ursodeoxycholic acid?